DE1643035A1 - Process for the production of new 15ss, 16ss-methylene-5alpha-androst-1-ene - Google Patents
Process for the production of new 15ss, 16ss-methylene-5alpha-androst-1-eneInfo
- Publication number
- DE1643035A1 DE1643035A1 DE19671643035 DE1643035A DE1643035A1 DE 1643035 A1 DE1643035 A1 DE 1643035A1 DE 19671643035 DE19671643035 DE 19671643035 DE 1643035 A DE1643035 A DE 1643035A DE 1643035 A1 DE1643035 A1 DE 1643035A1
- Authority
- DE
- Germany
- Prior art keywords
- androst
- methylene
- methylen
- acid
- anabolic effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 11
- 238000004519 manufacturing process Methods 0.000 title description 5
- 239000002253 acid Substances 0.000 claims description 11
- 230000001195 anabolic effect Effects 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 6
- 150000003431 steroids Chemical class 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 230000031709 bromination Effects 0.000 claims description 2
- 238000005893 bromination reaction Methods 0.000 claims description 2
- 238000007269 dehydrobromination reaction Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 11
- 239000005457 ice water Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000001548 androgenic effect Effects 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- LYQLGOGKDQKQAX-QYXZOKGRSA-N (5s,8s,9s,10r,13s,14s)-10,13-dimethyl-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 LYQLGOGKDQKQAX-QYXZOKGRSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 239000003263 anabolic agent Substances 0.000 description 2
- 229940070021 anabolic steroids Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000006356 dehydrogenation reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 229960001712 testosterone propionate Drugs 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- VMNRNUNYBVFVQI-QYXZOKGRSA-N (5s,8s,9s,10s,13s,14s)-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CCC[C@@]2(C)CC1 VMNRNUNYBVFVQI-QYXZOKGRSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- FOTITZRWZUAVPH-UHFFFAOYSA-N 2-phenylpropanoyl chloride Chemical compound ClC(=O)C(C)C1=CC=CC=C1 FOTITZRWZUAVPH-UHFFFAOYSA-N 0.000 description 1
- -1 3,3 ethylenedioxy-5a-androst-15-en-17-one Chemical compound 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 206010049438 General physical health deterioration Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- IKJYSRHIFAPYNT-UHFFFAOYSA-N O1CCCC1.[Br] Chemical compound O1CCCC1.[Br] IKJYSRHIFAPYNT-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000001612 cachectic effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 238000006567 deketalization reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- DAPZDAPTZFJZTO-UHFFFAOYSA-N heptanoyl heptanoate Chemical compound CCCCCCC(=O)OC(=O)CCCCCC DAPZDAPTZFJZTO-UHFFFAOYSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- JGJLWPGRMCADHB-UHFFFAOYSA-N hypobromite Inorganic materials Br[O-] JGJLWPGRMCADHB-UHFFFAOYSA-N 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000005907 ketalization reaction Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- BPLKQGGAXWRFOE-UHFFFAOYSA-M trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Steroid Compounds (AREA)
Description
' Verfahren zur Herstellung neuer 15B,16B-Methylen-5a-androst-l-ene Die Erfindung betrifft ein Verfahren zur Herstellung neuer 15-ß,16B-Methylen-5a-androst--l-ene der allgemeinen Formel worin R ein Wasserstoffatom, einen Alkyl- oder einen ge- sättigten sauerstoff-heterocyclischen Rest oder einen physiologisch verträglichen Säurerest bedeutet, dadurch gekenn- zeichnet, dafl man in entsprechende, im A-Ring gesättigte, Steroide in an sich bekannter Weise eine 1(2)-etändige Doppelbindung einführt und - je nach der letztlich gewünschten Bedeutung von R - die erhaltenen Primärprodukte gegebenenfalls anschließend in 17-Stellung veräthert, verestert oder vor- seift. _ Die Erfindung betrifft weiter-hin Verbindungen der.allgeaeinen* Pormel I. Als Alkylreste sind vorzugsweise niedere Reste, wie Methyl Lmd Äthyl geeignet, als gesättigter sauerstoffheterocyclischer - Rest kommt insbesondere der Tetrahydropyranylrest infrage. Process for the production of new 15B, 16B-methylene-5a-androst-l-enes The invention relates to a process for the production of new 15-ß, 16B-methylene-5a-androst-l-enes of the general formula wherein R is a hydrogen atom, an alkyl or an overall saturated oxygen-heterocyclic group or a physiologically acceptable acid residue, characterized marked by one DAFL into corresponding, saturated in the A ring, steroids in per se known manner, a 1 (2 ) introduces permanent double bond and - depending on the ultimately desired meaning of R - optionally then etherifies, esterifies or pre- soaps the primary products obtained in the 17-position. The invention also relates to compounds of the general formula I. Lower radicals such as methyl and ethyl are preferably suitable as alkyl radicals; the tetrahydropyranyl radical is particularly suitable as the saturated oxygen-heterocyclic radical.
Als physiologisch verträgliche Säurereste sollen alle in der Steroidchemie üblicherweise angewandten Säurereste verstandenwerden. Bevorzugt sind die Reste von Carbonsäuren mit bis zu 16 Kohlenstoffatomen. Die-Säuren-können auch ungesättigt, verzweigt, mehrbasisch oder in üblicher Weise, beispielsweise durch Hydroxy-, Aminogruppen oder Halogenatome, substituiert sein. Geeignet sind auch die Reste cyeloaliphatischer, aromatischer, gemischt aromatisch-aliphatiseher und heterocyclischer Säuren, die ebenfalls substituiert sein können. Als bevorzugte Säuren-zur Ausbildung des Restes R seien beispielsweise genannt: Essigsäure, Propionsäure, Capronsäure, Önanthsäure, Undeoylsäure, Palmitinsäure, Trimethylessigsäure, Mono-, Di- und Triohloressigsäure, Phenylessigsäure, Phenoxyessigsäure, Dialkyl- -aminoeseigsäure, Piperidinoesoigaäure, Nieotinsäure, Cyclopentylpropiönsäure, Milchsäure, Bernsteinsäure, Benzoesäure u. ä., ferner die gebräuchliohen anorganischen Säuren, wie Phosphor-und Schwefelsäure.As physiologically acceptable acid residues, all should be used in steroid chemistry commonly used acid residues can be understood. The radicals are preferred of carboxylic acids with up to 16 carbon atoms. The acids can also be unsaturated, branched, polybasic or in the customary manner, for example by means of hydroxyl or amino groups or halogen atoms. The residues of cyeloaliphatic, aromatic, mixed aromatic-aliphatic and heterocyclic acids, the can also be substituted. As preferred acids to form the remainder Examples of R are: acetic acid, propionic acid, caproic acid, enanthic acid, Undeoylic acid, palmitic acid, trimethyl acetic acid, mono-, di- and trio-chloroacetic acid, Phenylacetic acid, phenoxyacetic acid, dialkylaminoesetic acid, piperidinoesoiga acid, Nieotinic acid, cyclopentylpropionic acid, lactic acid, succinic acid, benzoic acid and the like. Ä., Also the common inorganic acids, such as phosphoric and sulfuric acid.
Die erfindungsgemäße Einführung der Doppelbindung in 1,2-Stellurig des Steroidgorüstee erfolgt in an sich bekannter Weise. Zur Einführung der,Doppelbindung durch Dehydrierung wird beispielsweise das gesättigte 5a H-3-Keton in einem inerten Lösungsmittel gelöst und mit einem Dehydrierungsmittel, wie 2,3-Dichlor-5,6-dicyan-benzochinon, erhitzt. Als Lösungsmittel kommen solche infrage, die gegen das eingesetzte Dehydrierungämittel inert sind, wie beispielsweise Dioxan, Benzol, Toluol, tert.-Butanol u. ä.The introduction of the double bond according to the invention in the 1,2-position of the steroid structure takes place in a manner known per se. To introduce the double bond by dehydrogenation, for example, the saturated 5a H-3-ketone is dissolved in an inert solvent and heated with a dehydrogenating agent such as 2,3-dichloro-5,6-dicyano-benzoquinone. Possible solvents are those which are inert to the dehydrogenating agent used, such as, for example, dioxane, benzene, toluene, tert-butanol and the like.
Die Methode der direkten Dehydrierung ist jedoch mit einigen Nachteilen verbunden. So bereitet insbesondere bei der Aufarbeitung größerer Ansätze die Abtrennung des reduzierten bzw, unverbrauchten Dehydrierungsmittels gewisse Schwierigkeiten. Außerdem kann es bei der chemischen und auch bei der biologischen Dehydrierung leicht geschehen, daß die Dehydrierung nicht auf der Stufe der LH-Verbindung stehenbleibt, so daß man jedesmal Anteile an der entsprechenden erhält. Aus diesen Gründen hat sich zur Einführung einer A1-Doppelbindung neben der direkten Dehydrierung insbesondere die Halogenierung des 5a-H-3 Ketons in 2-Stellung und anschließende Halogenwasserstoffabspalturig bewährt. -Nach einer bevorzugten Ausführungsform wird das im A-Ring gesättigte Ausgangssteroid in Tetrahydrofuran gelöst und mit einer Lösung von Brom in Eisessig bromiert. Die aus der Reaktionslösung mit Eiswasser gefällte und in üblicher Weise isolierte 2-Bromverbindung wird zur Bromwasseratoffabspaltung in einem inerten Lösungsmittel, vorzugsweise in Dimethylformamid, mit einem Alkalihalogenid, wie.Dithiumchlorid oder -bromid, vorzugsweise in Gegenwart eines Alkali- oder Erdalkaliz:arbonats, wie Lithium- oder Calciumcarbonat, bei erhöhter Temperatur umgesetzt. Die Reaktionszeit richtet sich nach der Temperatur, bei der die Bromwasseratoffabapaltung vorgenommen wird. Sie beträgt zum Beispiel bei einer Reaktionstemperatur von 1150 C ca. 5 Stunden. Zweckmäßigerweise wird die Bromwasseratoffabapaltung unter Ausschluß von Luftsauerstoff, vorzugsweise in Gegenwart eines Schutzgases, wie Stickstoff oder Argon, durchgeführt. Die Bromierung kann außer mit Brom auch mit bromhaltigen Verbindungen, wie N-Bromsuccinimid, vorgenommen werden. Darüber hinaus ist eine Halogenierung auch mit Chlor möglich.However, the direct dehydration method has several disadvantages. For example, when working up larger batches, separating off the reduced or unconsumed dehydrating agent presents certain difficulties. In addition, it can easily happen in chemical and biological dehydration that the dehydration does not stop at the level of the LH compound, so that proportions of the corresponding one are obtained each time. For these reasons, in addition to direct dehydrogenation, halogenation of the 5a-H-3 ketone in the 2-position and subsequent elimination of hydrogen halide has proven useful for introducing an A1 double bond. According to a preferred embodiment, the starting steroid saturated in the A-ring is dissolved in tetrahydrofuran and brominated with a solution of bromine in glacial acetic acid. The 2-bromine compound, which is precipitated from the reaction solution with ice water and isolated in the usual way, is used for splitting off Bromwasseratoff in an inert solvent, preferably in dimethylformamide, with an alkali halide, wie.Dithiumchlorid or bromide, preferably in the presence of an alkali or alkaline earth metal: carbonate, such as Lithium or calcium carbonate, converted at an elevated temperature. The reaction time depends on the temperature at which the Bromwasseratoffabapaltung is carried out. For example, at a reaction temperature of 1150 C it is approx. 5 hours. The elimination of bromine water is expediently carried out with the exclusion of atmospheric oxygen, preferably in the presence of a protective gas such as nitrogen or argon. In addition to bromine, the bromination can also be carried out using bromine-containing compounds such as N-bromosuccinimide. Halogenation with chlorine is also possible.
Die erfindungsgemäß herstellbaren 15ß,16ß-Methylen-5a-androst-1-ene sind starke Anabolika mit besonders günstiger Differenzierung der anabolen und androgenen Wirkung. Sie lassen sich aubeutan, aber auch per os anwenden.The 15β, 16β-methylene-5α-androst-1-enes which can be prepared according to the invention are strong anabolic steroids with a particularly favorable differentiation of the anabolic and androgenic effects. They can be used externally, but also per os.
In der folgenden Tabelle sind die Werte für die anabole und androgene
Wirkung der neuen Verbindungen am Beispiel des 17ß-Aoetoay-15ß,16ß-methylen-5a-androst-l-en-3-ons
dem als Standardeubatanz gebräuchlichen Testosteronpropionat und dem unsubstituierten
17ß-Aeetoxyy5a-androst-l-en-3-on
vergleichend gegenübergestellt. Die Werte wurden im üblichen hevator-ani-Samenblasentest
an kastrierten Rattenböcken bestimmt, nachdem den Versuchstieren im Verlauf von
14.Tagen die angegebene Dosis zwölfmal subeutan appliziert worden war.
Die neuen Verfahrensprodukte sollen in Verbindung mit den in der galenischen Pharmazie bekannten und üblichen Trägerstoffen zur Herstellung anabol wirksamer, suboutan bzvr. oral anwendbarer, Arzneimittel dienen. Die Ester unter den erfindungsgemäßen Steroiden, in denen sich der Esterrest von- einer höheren Fettsäure ableitet, sind aufgrund ihrer protrahierten Wirkung insbesondere-geeignet zur Herstellung entsprechender Depotpräparate.The new process products should be used in conjunction with those in the galenical Pharmaceutical known and common carriers for the production of anabolic effective, suboutan or vr. more oral, Medicinal serve. The esters among the steroids according to the invention in which the ester radical is from a higher Fatty acid derived are particularly-suitable due to their protracted effect for the production of corresponding depot preparations.
Die neuen Wirkstoffe sind bei allen Indikationen anwendbar, bei denen eine Förderung des Eiweißanbaus durch Anabolika erforderlich ist. Beispielsweise seien folgende Indikationen genannt: Rekonvaleszenz, reduzierter Allgemeinzustand, konsumierende Erkrankungen, kachektisehe Zustände, Appetitmangel, Untergewicht, Erschöpfung, Strahlentherapie, Anämie, Langzeitbehandlung mit Kortikoiden, Osteoporose, chronische Nierenerkrankungen usw.The new active ingredients can be used for all indications for which a promotion of the protein cultivation by anabolic steroids is necessary. For example the following indications are mentioned: convalescence, reduced general condition, consuming diseases, cachectic conditions, lack of appetite, underweight, Exhaustion, radiation therapy, anemia, long-term treatment with corticosteroids, osteoporosis, chronic kidney disease, etc.
Die als Ausgangsstoffe für das erfindungsgemäße Verfahren verwendeten
158,168 Methylen-5a-androstanolone können nach an sich bekannten Methoden, beispielsweise
wie folgt, hergestellt werden: 175 ml Dimethyleulfoxid, 1,44 g Natriumhydrid und
13,25 g Trimethyloxosulfoniumjodid werden bei Raumtemperatur bis zum Ende der Gasentwicklung
(es, 4o Minuten) gerührt. Dann werden 16,5 g 3,3 Äthylendioxy-5a-androst-15-en-17-on
(F. 148,5-149,5o C; hergestellt aus 17,17 Äthylendioxy-5a-
9,5 g 17ß-Hydroxy-15ß,16ß-methylen-5a-androstan-3-on (Rohprodukt) werden in 2o ml Pyridin und 10 ml Aeetanhydrid ge-UIdt und über Nacht bei Raumtemperatur stehen gelassen. Nach Eiswasserfällung isoliert man in üblicher Weise 10 g Rohprodukt, das aus Diisopropyläther umkristallisiert wird, Es werden 7,95 g 17ß-Acetoxy-15ß,16ß-methylen-5a-androstan-3-on vom Schmelzpunkt 181,5-183o C erhalten, B e i s p i e 1 1: a) Zu einer gerührten Lösung von-5,75 g 17ß-Aoetoxy-15ß,16ßmethylen-5a-androstan-3-on in 50 ml Tetrahydrofuran tropft man im Verlaufe von 30 Minuten eine Lösung von 0,855 ml Brom in 7 ml Eisessig und rührt 10 Minuten nach, Das nach Eiswasserfällung isolierte Rohprodukt (6,8 g) kristallisiert man aus Diisopropyläther um und erhält 5,75 g 2a-Brom-17ß-aoetoxy-.15ß,16ß-methylen-5a-androstan-3-on vom Schmelzpunkt 200-2020 C (Z.).9.5 g of 17β-hydroxy-15β, 16β-methylen-5a-androstan-3-one (crude product) are ge-UIdt in 20 ml of pyridine and 10 ml of anhydride and left to stand overnight at room temperature. After precipitation with ice water, 10 g of crude product are isolated in the usual way, which is recrystallized from diisopropyl ether. B eis p ie 11: a) A solution of 0.855 ml is added dropwise over 30 minutes to a stirred solution of -5.75 g of 17β-aoetoxy-15β, 16β-methylene-5α-androstan-3-one in 50 ml of tetrahydrofuran Bromine in 7 ml of glacial acetic acid and stirred for 10 minutes. The crude product isolated after ice-water precipitation (6.8 g) is recrystallized from diisopropyl ether and 5.75 g of 2a-bromo-17ß-aoetoxy-.15ß, 16ß-methylene-5a- androstan-3-one of melting point 200-2020 C (Z.).
b) 5,75 g 2a-Brom-17ß-aoetoxy-15ß,16ß-methylen-5a-androstan-3-on werden
in 216 ml Dimethylformamid gelöst. Dann werden 22,8 g Calciumcarbonat und 12,1 g
Lithiumbromid ein-
B e i s p i e 1 3: 2,56 g 17ß-Aoetoxy-15ß,16ß-methylen-5a-androst-l-en-3-on werden in 25o ml dest. Methanol gelöst. Nach Zugabe von 25 ml Wasser und 2,3 g Kaliumcarbonat wird 1 Stunde unter Stickstoff zum Sieden erhitzt. Dann wird im Vakuum etwa auf 1/3 des Volumens eingeengt, in Eiswasser gegossen, der Niederschlag abfiltriert, ausgewaschen und getrocknet. Man erhält 2,4 g 17ß-Hydroxy-15ß,16ß-methylen-5a-androst-l-en-3-on vom Sohmelzpunkt 145,5-149o 0.Example 1 3: 2.56 g of 17β-aoetoxy-15β, 16β-methylen-5a-androst-1-en-3-one are in 25o ml of dist. Dissolved methanol. After adding 25 ml of water and 2.3 g of potassium carbonate is heated to boiling under nitrogen for 1 hour. Then in the vacuum about on 1/3 of the volume concentrated, poured into ice water, the precipitate filtered off, washed out and dried. 2.4 g of 17β-hydroxy-15β, 16β-methylen-5a-androst-1-en-3-one are obtained from Sohmelzpunkt 145.5-149o 0.
B e i s p i e 1 4: 600 mg 17ß-Hydroxy-15ß,16ß-methylen-5a-androst-l-en-3-on
werden in 2,4 ml Pyridin und 1,2 ml Propionsäureanhydrid 24 Stunden bei Raumtemperatur
stehen gelassen. Anschließend wird das Reaktionegemisch in Eiswasser gegossen, der
Niederschlag abfiltriert, ausgewaschen und getrocknet. Man erhält nach Umkristallisation
aus Diisopropyläther 300 mg 17ß PropionYl-
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DESC041140 | 1967-08-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE1643035A1 true DE1643035A1 (en) | 1971-04-15 |
| DE1643035B2 DE1643035B2 (en) | 1976-01-15 |
Family
ID=7436058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19671643035 Granted DE1643035B2 (en) | 1967-08-11 | 1967-08-11 | 15BETA, 16BETA-METHYLEN-5ALPHA -ANDROST-L-ENE, PROCESS FOR THEIR MANUFACTURING AND THE PRODUCTS CONTAINED |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE1643035B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2181720A1 (en) * | 1972-02-11 | 1973-12-07 | Schering Ag |
-
1967
- 1967-08-11 DE DE19671643035 patent/DE1643035B2/en active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2181720A1 (en) * | 1972-02-11 | 1973-12-07 | Schering Ag |
Also Published As
| Publication number | Publication date |
|---|---|
| DE1643035B2 (en) | 1976-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1618830C3 (en) | 11 beta-OB-13beta-C-gona-1,3,5 (10) -trienes containing oxygen in the 3 and 17 positions and process for their preparation | |
| DE1468950B2 (en) | ||
| DE2715863A1 (en) | PROCESS FOR THE PRODUCTION OF STEROID CARBONIC ACIDS AND THEIR ESTERS | |
| DE1298993B (en) | 3-Oxo-8ª ‡ -17ª ‰ -hydroxy-17ª ‡ -aethynyl-oestr-5 (10) -ene in its racemic and levorotatory form and process for the preparation of these compounds | |
| DE1643035A1 (en) | Process for the production of new 15ss, 16ss-methylene-5alpha-androst-1-ene | |
| DE1768700B1 (en) | Unsaturated 2,2-dimethyl steroids of the OEstran or Gonan series and process for their production | |
| Oliveto et al. | 11-Oxygenated Steroids. XI. The Synthesis of 17α-Hydroxycorticosterone (Compound F) 21-Acetate from Pregnane-11β, 17α-diol-3, 20-dione | |
| DE1668205C3 (en) | 16 alpha-alkylthio-9beta, lOalpha steroids, processes for their preparation and pharmaceutical preparations containing them | |
| AT267088B (en) | Process for the production of new 1,2α-methylene-19-nor-testosterone | |
| AT274256B (en) | Process for the preparation of 3-oxo-4,9,11-triene steroids | |
| DE1593501A1 (en) | 15,16ss-methylene steroids of the 19-nor-androstane series | |
| DE1493164C3 (en) | lbeta-halomethylandrostanes and process for their preparation | |
| DE1966921C3 (en) | 17 alpha-propadienyl-substituted 3-ketosteroids and process for their preparation | |
| DE1668687A1 (en) | New 18-methyl-5alpha-H-androstane | |
| DE1468632C (en) | öalpha Acetylthio 4 en 3 on steroids and process for their production | |
| DE1643050C3 (en) | 15 beta, 16 beta-methylene steroids, processes for their production and agents containing them | |
| DE956954C (en) | Process for the preparation of pregnane-16-01-3, 20-dione unsaturated in the 4-position | |
| AT235477B (en) | Process for the preparation of new steroid compounds condensed with an isoxazole ring | |
| DE1493163C3 (en) | nalpha-ethynyl-ie-methyl-delta high 4-oestrene-3 beta-17 betadiols, processes for their preparation and agents containing them | |
| DE1618829C (en) | Process for the production of 3 OA 11 beta OB 13beta C 17alpha R 17beta OE gona 1,3,5 (10) tons | |
| DE1298528B (en) | Process for the preparation of 3-oxo-13ª-alkyl-steroid-4,9,11-trienes | |
| DE1643054A1 (en) | New 7-methyl steroids | |
| DE1062698B (en) | Process for the preparation of preferably lower alkyl ethers of tertiary steroid alcohols | |
| DE2241731B2 (en) | Triene steroid compounds, processes and intermediates for their preparation, and pharmaceutical compositions containing them | |
| DE1249268B (en) | Process for the preparation of 17a-dimethyl - A1 - androstcnolondenvaten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| E77 | Valid patent as to the heymanns-index 1977 | ||
| 8339 | Ceased/non-payment of the annual fee |